Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug interaction study of Foscenvivint with CYP3A inhibitors in healthy male volunteers
jRCT2031240671Phase 1Completed
- Sponsor
- Ohara Pharmaceutical Co., Ltd.
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of foscenvivint, sponsored by Ohara Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetics. Started Mar 2025; status: completed.
02
Drugs
foscenvivint
Beyond the preview
Go deeper on jRCT2031240671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240671.